v3.26.1
SCHEDULE OF BASIC AND DILUTED LOSS PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Earnings Per Share [Abstract]    
Net loss from continuing operation attributable to stockholders $ (3,443) $ (4,165)
Net loss from discontinued operations attributable to stockholders (561) (1,028)
Net loss attributable to the Company’s stockholders’ equity (4,004) (5,193)
Net loss from continuing operation attributable to stockholders (3,443)
Adjustment for change in fair value of warrant liabilities (2,429)
Adjusted net loss from continuing operations used for diluted loss per share $ (5,872)
Weighted average number of shares of Common Stock used in basic loss per share [1],[2] 1,132,707 187,215
Effects of dilutive securities 155,542,000
Weighted average number of shares used in diluted earnings (loss) per share [1] 1,288,249 187,215
Basic loss per share from continuing operations attributable to stockholders [1] $ (3.04) $ (22.25)
Basic loss per share from discontinued operations attributable to stockholders [1] (0.50) (5.49)
Basic loss per share attributable to stockholders (3.54) (27.74)
Diluted loss per share from continuing operations attributable to stockholders [1] (8.11) (22.25)
Diluted loss per share from discontinued operations attributable to stockholders [1] (0.50) (5.49)
Diluted loss per share attributable to stockholders $ (8.61) $ (27.74)
[1] Adjusted to reflect one (1) for thirty-five (35) reverse stock split in September 2025 (see note 1B).
[2] The increase in the weighted average number of shares of common stock outstanding for the year ended December 31, 2025 compared to 2024 reflects shares issued in connection with the MitoCareX acquisition, issuances of common stock under the Company’s PIPE Agreement and SEPA II (including shares issued upon the exercise of warrants issued as part of the PIPE Agreement), and issuances of common stock to service providers and officers.